Glufimet
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | RGPU-238; Dimethyl 3-phenylglutamic acid hydrochloride; Dimethyl 3-phenylglutamate hydrochloride; 1,5-Dimethyl (2S)-2-amino-3-phenylpentanedioate hydrochloride |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H18ClNO4 |
| Molar mass | 287.74 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Glufimet (developmental code name RGPU-238), also known as dimethyl 3-phenylglutamate hydrochloride, is a derivative of glutamic acid (glutamate) which was developed in Russia and is related to the γ-aminobutyric acid (GABA) derivative phenibut (3-phenyl-GABA). It contains phenibut and glycine fragments in its chemical structure, has been described as a "GABA precursor", and is said to modulate the GABA and nitric oxide (NO) systems and to have antioxidant activity. It has been suggested that metabotropic glutamate receptors may also play a role in the mechanism of action of glufimet.Stress-protective effects have been described for glufimet in animals.
| |||||||||||||||||||||||||||||||||||||
| Forms | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
||||||||||||||
|
NO donors (prodrugs) |
|
||||||||||||||
|
Enzyme (inhibitors) |
|
||||||||||||||
| Others |
|
||||||||||||||
See also: Receptor/signaling modulators | |||||||||||||||